On March 10, 2026, Eli Lilly quietly announced something most American business journalists missed. The world’s most valuable pharmaceutical company would build a new Lilly Gateway Labs site — a research incubator hosting up to 30 emerging biotech companies. However, the location wasn’t Boston. It wasn’t San Francisco. Instead, it was Songdo, a reclaimed-land business district on the western coast of South Korea.
For anyone tracking the Korea K-Bio CDMO 2026 story, that single press release captured everything. In particular, the world’s biggest drug companies are no longer treating Korea as a low-cost manufacturing partner. Rather, they are treating it as a strategic anchor for their global supply chain. Meanwhile, the catalyst for this shift came not from Seoul, but from Washington.
This article unpacks how a single piece of US legislation rewired the global biopharma map — and why Korean biopharma manufacturing now sits at the center of one of Asia’s most consequential industrial bets. Specifically, we cover the BIOSECURE Act effect, the rise of Samsung Biologics to global Top 3, the Songdo cluster’s emergence as Asia’s bio capital, and the foreign capital quietly flooding into Lotte Biologics, Celltrion, and SK pharmteco. For broader context on Korea’s industrial transformation, see our coverage of Korea’s Top 10 Scale-Ups 2026 and the Korea Hydrogen Industry 2026 buildout.
To understand the Korea K-Bio CDMO 2026 boom, start with a piece of American legislation. On December 18, 2025, the United States enacted the FY2026 National Defense Authorization Act. Tucked inside Section 851 was the BIOSECURE Act — legislation that had failed to pass twice before but finally became law as part of the defense bill. The provisions prohibit federal agencies and government contractors from using biotechnology equipment or services from designated “biotechnology companies of concern” — primarily entities tied to foreign adversary governments.
The targets were familiar to anyone who had followed the bill’s two-year journey. WuXi AppTec, WuXi Biologics, and BGI Group had spent two decades becoming indispensable to American drug development. As a result, roughly 80% of US biopharma companies relied on Chinese partners for at least part of their pipeline. However, the enacted version of BIOSECURE links directly to the Department of Defense’s 1260H list of “Chinese military companies.” Furthermore, it creates a process for the Office of Management and Budget to designate additional companies. By December 2026, OMB must publish a complete list of biotechnology companies of concern. Restrictions then phase in through 2027 and beyond.
The numbers tell the story. According to industry analysts, this single piece of legislation could redirect roughly $30 billion in CDMO contracts away from China-linked providers over the next decade. Consequently, the question for Big Pharma became urgent. Where should that capacity move?
In particular, three options emerged. The United States offered political safety but lacked sufficient bioreactor capacity. Europe had quality but limited scale. Meanwhile, South Korea had something neither could match. It already operated the world’s largest single-site biomanufacturing campus.
That campus sits in Songdo. Furthermore, it belongs to Samsung Biologics.
For years, Western analysts treated Samsung Biologics as a curiosity — a Korean conglomerate’s attempt to muscle into a market dominated by Switzerland’s Lonza and China’s WuXi Biologics. However, by late 2025, that framing collapsed entirely. The Korea Biotechnology Industry Organization, citing MarketsandMarkets data, formally ranked Samsung Biologics as the world’s third-largest CDMO. Lonza held first place at roughly $7.5 billion in revenue. WuXi Biologics sat at $2.8 billion. In contrast, Samsung Biologics posted approximately $3.2 billion.
Moreover, the trajectory steepened in 2026. In Q1 alone, Samsung Biologics reported revenue of 1.257 trillion won — up 25.8% year-over-year. Operating profit hit 581 billion won. The company’s batch success rate sat at roughly 99% across more than 440 regulatory approvals since 2011. For Big Pharma clients evaluating where to bet billions in commercial manufacturing, those numbers matter enormously.
The capacity story is even more striking. After full operation of its 180,000-liter Plant 5 at the Songdo campus in 2025, Samsung Biologics now operates 785,000 liters across Korea. In addition, the company closed a $280 million acquisition of GSK’s Rockville, Maryland facility in Q1 2026. As a result, total global manufacturing capacity reached 845,000 liters. For reference, that is more biomanufacturing capacity than the entire Japanese CDMO sector combined.
CEO John Rim laid out a “three-pillar expansion strategy” at the J.P. Morgan Healthcare Conference 2026 in San Francisco. Specifically, those pillars are manufacturing capacity, portfolio breadth, and global footprint. Notably, only 25 of roughly 500 presenting companies earn the Grand Ballroom slot at JPM. Samsung Biologics has presented there for ten consecutive years.
The third Bio Campus is already in motion. In late 2025, the company signed a 248.7 billion won land purchase agreement with the Incheon Free Economic Zone Authority for an additional 187,427 square meters in Songdo. Meanwhile, the new site will support production of antibody-drug conjugates, antibody vaccines, peptides, and cell and gene therapies — the next-generation modalities driving the post-2027 biopharma wave.
For investors and corporate development teams reading the Korean CDMO industry signals, one detail matters most. In November 2025, Samsung Biologics completed a corporate spin-off of its biosimilar investment business into a new entity called Samsung Epis Holdings. Consequently, Samsung Biologics is now a pure-play CDMO. The structural change removes any conflict of interest with potential pharma clients. Furthermore, it signals that the parent company is doubling down on contract manufacturing as the long-term growth engine.
Step back from individual companies, and the Korea K-Bio CDMO 2026 story becomes geographic. In particular, almost every major Korean biopharma manufacturing facility now sits within a single concentrated zone — the Songdo Bio Cluster in Incheon Free Economic Zone (IFEZ), about an hour’s drive from central Seoul.
The cluster’s anchor tenants read like a who’s who of global biomanufacturing. Samsung Biologics holds three campuses spanning roughly half a million square meters. Celltrion runs its corporate headquarters and original biosimilar plants there. Furthermore, Lotte Biologics is constructing a $3.3 billion biocampus on adjacent land. In addition, Cytiva — the global life sciences supplier owned by Danaher — opened its first APAC Innovation Hub in Songdo with a manufacturing unit slated to begin local production in 2026.
The Lilly Gateway Labs deal completes the picture. The five-story, 125,000-square-foot facility will sit inside Samsung Biologics’ Bio Campus II. As a result, up to 30 early-stage biotech companies — selected jointly by Lilly and Samsung — will gain access to laboratory space, research infrastructure, and Lilly’s global scientific network. The site is expected to open in July 2027. For comparison, Lilly’s Gateway Labs sites in San Francisco, Boston, San Diego, and New York host similar incubators in the heart of America’s bio innovation hubs. Notably, Songdo is now on that map.
The Korean government has reinforced the cluster aggressively. In January 2025, it launched the National Bio Committee — a presidential advisory body coordinating national biotech strategy. Meanwhile, the Bio Economy 2.0 Initiative aims to position Korea as a global leader in bio-medical products, materials, energy, and digital bio innovation by 2030. In addition, a proposed Biopharmaceutical CDMO Support Act would give registered CDMOs streamlined regulatory treatment and tax incentives.
For foreign founders and R&D talent considering Korea, the Songdo cluster offers something rare in Asia. It combines world-class manufacturing infrastructure with proximity to two international airports, English-friendly business services, and a free economic zone tax structure. Additionally, the OASIS startup visa program now extends recommendation authority to local governments and accredited accelerators — making it easier for foreign biotech founders to relocate.
While Samsung Biologics dominates headlines, Lotte Biologics is executing one of the most aggressive late-entry plays in global CDMO history. The company didn’t exist before 2022. However, by 2030, CEO James Park has publicly committed to becoming a global Top 10 CDMO. The capital backing that ambition is real — roughly 4.6 trillion won, or about $3.3 billion.
The strategy rests on dual hubs. First, Lotte Biologics acquired Bristol-Myers Squibb’s biologics manufacturing facility in Syracuse, New York, in 2022. The site provides 40,000 liters of drug substance capacity plus a newly completed antibody-drug conjugate (ADC) facility. Second, the Songdo Bio Campus broke ground in 2024. Specifically, three plants of 120,000 liters each will come online sequentially. Plant 1 is scheduled for commercial operation in 2027. Furthermore, Plants 2 and 3 will follow by 2030. Once complete, total capacity will reach 400,000 liters.
The Syracuse-Songdo split serves a specific purpose. In particular, Syracuse functions as a “one-stop CDMO hub from antibody to ADC” for North American clients. Meanwhile, Songdo will operate as the large-scale commercial production base. For US biotech companies navigating BIOSECURE Act compliance, this dual-geography structure offers a compelling alternative to building entirely new domestic capacity. Furthermore, this dual-geography model represents one of the most distinctive plays in the broader Korea K-Bio CDMO 2026 landscape.
The company’s traction is improving. In April 2026, Lotte Biologics signed a CDMO agreement with a US oncology biotech for late-stage clinical antibody production. Additionally, the deal extends through commercialization stages — a meaningful step beyond pure clinical sample work. Earlier wins include a 2025 ADC clinical candidate contract with an Asian biotech firm.
However, the path to Top 10 status will not be smooth. Lotte Biologics posted an operating loss of 80.1 billion won in 2024 — a sharp swing from a 26.6 billion won profit in 2023. Investment expansion continues to outpace revenue. For investors, the question is whether Lotte’s parent conglomerate has the patience to fund the buildout through 2030.
Celltrion is the other Korean biopharma name foreign investors should know — but for a different reason. The Incheon-based company built its global reputation on biosimilars. In particular, drugs like Remsima (an infliximab biosimilar) and Truxima (a rituximab biosimilar) have generated billions in cumulative sales across Europe and the United States.
However, Celltrion is now leaning into CDMO services as a parallel growth engine. In December 2025, the company announced it would invest 700 billion won (roughly $478 million) to expand a former Eli Lilly active pharmaceutical ingredient manufacturing facility. Furthermore, Celltrion launched a dedicated CDMO subsidiary called Celltrion Biosolutions. As a result, the company acquired a plant in Branchburg, New Jersey — adding 66,000 liters of capacity with plans to double that figure to 132,000 liters.
The strategic logic is clear. Celltrion already operates GMP-compliant manufacturing at scale. Moreover, the company has built deep regulatory relationships with the FDA and EMA over fifteen years of biosimilar approvals. Consequently, offering that infrastructure to external clients creates additional revenue without requiring new R&D investment. As a result, Celltrion is now positioning itself as a meaningful third pillar within the Korea K-Bio CDMO 2026 hierarchy alongside Samsung Biologics and Lotte.
At J.P. Morgan Healthcare Conference 2026, Celltrion presented on the main track alongside Samsung Biologics and Big Pharma giants like GSK and AstraZeneca. In addition, Alteogen — the largest biotech company by market cap on Korea’s KOSDAQ — joined D&D Pharmatech and Hugel on the APAC track. Notably, Alteogen’s ALT-B4 hyaluronidase technology has attracted major partnerships. AstraZeneca licensed it in March 2025 for subcutaneous oncology drug development. Additionally, Daiichi Sankyo signed a $1.7 billion deal in November 2024 for a subcutaneous version of ENHERTU.
Antibody-drug conjugates represent the fastest-growing modality in oncology. Specifically, ADCs combine the targeting precision of antibodies with the cell-killing power of cytotoxic chemotherapy. Furthermore, Big Pharma has poured tens of billions into ADC pipelines over the past three years. As a result, manufacturing capacity has become the bottleneck.
Korea is positioning itself directly into that bottleneck. In October 2025, Lotte Biologics and SK pharmteco signed a Letter of Intent for a strategic ADC partnership. The deal combines Lotte’s antibody drug substance and bioconjugation capabilities with SK pharmteco’s linker-payload chemistry expertise. Consequently, the joint platform offers global clients an integrated, one-stop ADC CDMO service spanning the entire production chain.
SK pharmteco itself is a fascinating case. The company operates production sites in the United States, Europe, and South Korea. Additionally, it sits under SK Inc., the strategic investment arm of Korea’s second-largest conglomerate. In February 2025, SK pharmteco announced a $260 million Sejong facility for small-molecule and peptide production — directly targeting the GLP-1 obesity drug boom led by Novo Nordisk and Eli Lilly.
Samsung Biologics is also pushing into ADCs. The third Bio Campus in Songdo will explicitly support ADC production at commercial scale. Meanwhile, the company launched a Samsung Organoids service in 2025, integrating patient-derived organoid platforms with its CDMO infrastructure. In particular, this allows clients to validate drug candidates against patient-specific cancer models before committing to large-scale manufacturing — a workflow innovation few Western CDMOs match.
The most telling signal of the Korea K-Bio CDMO 2026 moment is who is now writing checks. In particular, Eli Lilly’s Gateway Labs commitment represents far more than a real estate decision. Furthermore, it signals that the world’s most valuable drug company sees Korea as a strategic R&D anchor rather than a cost-arbitrage stop.
Cytiva’s Songdo Innovation Hub matters for similar reasons. Cytiva is owned by Danaher, the $200 billion American life sciences conglomerate. Specifically, the company makes the bioreactors, single-use systems, and chromatography equipment that fill every CDMO plant in the world. As a result, Cytiva’s decision to manufacture locally in Songdo rather than ship from the United States represents a long-term commitment to Korean demand.
The Coalition for Epidemic Preparedness Innovations (CEPI) is another major partner. In 2026, Samsung Biologics announced a CEPI partnership focused on rapid-response manufacturing for future pandemics. The deal positions Korea as a strategic node in global pandemic preparedness — a role that previously belonged almost exclusively to Western contractors.
Meanwhile, Korean public market investors have caught on. Samsung Biologics shares trade at a premium valuation reflecting structural growth expectations. In addition, Celltrion’s market cap consistently ranks among the largest on the KOSPI. For foreign portfolio investors, the K-Bio sector now offers what Korean semiconductors offered fifteen years ago — exposure to a structural global supply chain shift wrapped in a relatively liquid, English-disclosure equity market. For more on the broader equity context, see our Korea Stock Market 2026 analysis.
External resources worth bookmarking include BioSpace for global CDMO deal coverage, the J.P. Morgan Healthcare Conference which sets sector expectations every January, and BIO International Convention where most Korean biopharma manufacturing companies present annually.
No industry analysis is honest without the bear case. In particular, the Korea K-Bio CDMO 2026 story carries three meaningful risks.
The first risk is geopolitical dependence. Specifically, much of Korea’s current advantage flows from BIOSECURE Act enforcement against Chinese CDMOs. However, US legislation can shift. A new administration could weaken enforcement, grant exemptions, or simply allow compliance deadlines to slip. As a result, Korean CDMOs riding the BIOSECURE tailwind could face renewed Chinese competition by 2030.
The second risk is capacity oversupply. In particular, every major Korean player is racing to expand simultaneously. Samsung Biologics is building Bio Campus III. Meanwhile, Lotte Biologics is constructing three 120,000-liter plants. Furthermore, Celltrion is doubling its New Jersey capacity. If global biologics demand growth slows — perhaps due to a recession or regulatory headwind — Korean CDMOs could find themselves with utilization rates that crater margins.
The third risk is execution. Lotte Biologics in particular has yet to prove it can win meaningful commercial-scale contracts beyond its initial BMS-acquired book of business. Additionally, building a Top 10 CDMO requires not just capacity but global business development relationships that take decades to mature. Lonza has spent over a century building those relationships. Korean entrants must build them in years.
For prudent investors, the appropriate response is portfolio construction rather than concentration. In other words, exposure to Samsung Biologics offers proven execution. Lotte Biologics offers higher-beta optionality. Furthermore, Celltrion provides a biosimilar plus CDMO hybrid. Meanwhile, Alteogen represents pure technology licensing exposure.
The Korea K-Bio CDMO 2026 story is ultimately about positioning. Specifically, when the dust settles on the BIOSECURE-era reshoring, three or four global CDMO winners will emerge with structurally larger market shares. Korean players are explicitly engineered to be among them.
For foreign biotech founders, the practical implication is clear. Songdo is now a viable launch destination — particularly for ADC, peptide, and emerging modality companies seeking proximity to manufacturing partners. Furthermore, the Lilly Gateway Labs program offers a structured path with embedded scientific support.
For corporate development teams at Big Pharma, the message is equally direct. Diversifying away from Chinese CDMOs no longer requires choosing between expensive US capacity or unproven alternatives. As a result, Korean biopharma manufacturing offers FDA-grade quality, English-language business operations, and capacity at scale that genuinely competes with Lonza on a per-liter basis.
For portfolio investors, the calculation is about timing. In particular, Korean CDMO equities have already rerated significantly through 2025 and early 2026. However, the sector’s structural growth runway extends well into the 2030s. Specifically, the global biopharmaceutical CDMO market is projected to reach roughly $63.9 billion by 2032 — up from $25.7 billion in 2024. Consequently, even modest market share gains translate into substantial absolute revenue growth.
The deeper story, however, is industrial. For decades, Korea built its economy on memory chips, displays, ships, and cars. Each of those industries took roughly two decades to evolve from challenger to global category leader. Korean CDMO capacity is now roughly fifteen years into that same arc. Moreover, the BIOSECURE catalyst has compressed what might have been a slow climb into a steep acceleration.
Ten years from now, when biopharma analysts list the world’s most strategically important manufacturing locations, Songdo will likely sit alongside Basel, Boston, and Cambridge. Furthermore, the foreign investors, founders, and operators paying attention now are the ones positioned to benefit when that recognition becomes consensus.
For Korea, this is the next chapter after semiconductors. For everyone else, it is one of the cleanest structural growth stories in global healthcare today.
On a Wednesday at noon in November 2025, hundreds of people lined up along Bishop…
The 1 a.m. Tomato It is 1:14 in the morning in a Mapo-gu apartment. The…
The Moment Korea Stopped Browsing Korea live commerce 2026 looks like this. On a Tuesday…
On a cold Saturday morning in early March, a line stretched from the front door…
In the first quarter of 2025, roughly $40 billion leaked out of South Korean crypto…
In July 2022, a Polish delegation walked into a Hanwha Aerospace factory in Changwon. They…